Amyotrophic Lateral Sclerosis

Neurology·MeSH: Amyotrophic Lateral Sclerosis

Prevalence

5.0 / 100K

Incidence

2.0 / 100K/yr

51 drugs in development·31 companies·33 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Emylif® (licensed product, formerly Exservan® in U.S.)	Aquestive Therapeutics, Inc. (AQST)

Phase 3(12)

Drug	Company
ABBV-CLS-7262	Valneva SE (VALN)
CNM-Au8	Valneva SE (VALN)
DNL343	Valneva SE (VALN)
DNL343	Denali Therapeutics Inc. (DNLI)
ion363	IONIS PHARMACEUTICALS INC (IONS)
Latozinemab (AL001)	Alector, Inc. (ALEC)
NUZ-001	Valneva SE (VALN)
Pridopidine	Valneva SE (VALN)
SLS-005 Trehalose	Valneva SE (VALN)
Tofersen	BIOGEN INC. (BIIB)
Verdiperstat	Valneva SE (VALN)
Zilucoplan	Valneva SE (VALN)

Phase 2(15)

Drug	Company
AL001	Alector, Inc. (ALEC)
argx-119	ARGENX SE (ARGX)
Autologous Treg cell therapy	Coya Therapeutics, Inc. (COYA)
cnm-au8	Clene Inc. (CLNN)
cnmau8	Clene Inc. (CLNN)
COYA 301	Coya Therapeutics, Inc. (COYA)
COYA 302	Coya Therapeutics, Inc. (COYA)
COYA 303	Coya Therapeutics, Inc. (COYA)
primec	NeuroSense Therapeutics Ltd. (NRSN)
PTC857	PTC THERAPEUTICS, INC. (PTCT)
tegoprubart	Eledon Pharmaceuticals, Inc. (ELDN)
trehalose	SEELOS THERAPEUTICS, INC. (SEEL)
Utreloxastat	PTC THERAPEUTICS, INC. (PTCT)
vhb937	Novartis AG (NVS)
vhb937	Novartis AG (NVS)

Phase 1(9)

Drug	Company
Acetylcysteine	Crinetics Pharmaceuticals, Inc. (CRNX)
dazucorilant	CORCEPT THERAPEUTICS INC (CORT)
dnl747	Sanofi (SNY)
INS1202	INSMED Inc (INSM)
LY4256984	ELI LILLY & Co (LLY)
pas-003	Pasithea Therapeutics Corp. (KTTA)
Riluzole	ENANTA PHARMACEUTICALS INC (ENTA)
Riluzole	Crinetics Pharmaceuticals, Inc. (CRNX)
rinvatercept	Keros Therapeutics, Inc. (KROS)

Preclinical(8)

Drug	Company
aav-upf1	MeiraGTx Holdings plc (MGTX)
ALPHA-0602	Alpha Cognition Inc. (ACOG)
ALPHA-0702	Alpha Cognition Inc. (ACOG)
ALPHA-0802	Alpha Cognition Inc. (ACOG)
als program	Korro Bio, Inc. (KRRO)
rpi-78m	NUTRA PHARMA CORP (NPHC)
sod1 silencing gene therapy	Voyager Therapeutics, Inc. (VYGR)
undisclosed als program	Korro Bio, Inc. (KRRO)

Early Phase 1(1)

Drug	Company
Psilocybin	UNITED THERAPEUTICS Corp (UTHR)

Phase 1/Phase 2(1)

Drug	Company
amt-162	uniQure N.V. (QURE)

Phase 2/Phase 3(3)

Drug	Company
ath-1105	LeonaBio, Inc. (LONA)
mn-166	MEDICINOVA INC (MNOV)
sls-005	SEELOS THERAPEUTICS, INC. (SEEL)

Phase 4(1)

Drug	Company
Acetylcysteine	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 51 drugs in development for Amyotrophic Lateral Sclerosis across 31 companies.

There are 33 clinical trials targeting Amyotrophic Lateral Sclerosis tracked by BioSniper.

The estimated prevalence of Amyotrophic Lateral Sclerosis is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.